Adage Capital Partners
ABEO icon

Adage Capital Partners’s Abeona Therapeutics ABEO Stock Holding History

Adage Capital Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,047,985
Closed -$16.1M – 908
2025
Q3 		$16.1M Sell
3,047,985
-25,000
-0.8% -$159K 0.03% 531
2025
Q2 		$17.5M Buy
3,072,985
+381,357
+14% +$2.17M 0.03% 474
2025
Q1 		$12.8M Sell
2,691,628
-1,210,732
-31% -$6.58M 0.02% 532
2024
Q4 		$21.7M Buy
3,902,360
+652,366
+20% +$4.01M 0.04% 424
2024
Q3 		$20.5M Hold
3,249,994
– – 0.04% 441
2024
Q2 		$13.8M Hold
3,249,994
– – 0.03% 530
2024
Q1 		$23.6M Hold
3,249,994
– – 0.04% 405
2023
Q4 		$16.3M Hold
3,249,994
– – 0.03% 486
2023
Q3 		$13.7M Buy
3,249,994
+1,488,834
+85% +$5.63M 0.03% 498
2023
Q2 		$7.1M Buy
1,761,160
+430,000
+32% +$1.5M 0.02% 623
2023
Q1 		$3.75M Hold
1,331,160
– – 0.01% 735
2022
Q4 		$4.1M Buy
1,331,160
+1,010,870
+316% +$3.78M 0.01% 767
2022
Q3 		$974K Sell
320,290
-1
-0% -$4 ﹤0.01% 892
2022
Q2 		$1.67M Hold
320,291
– – ﹤0.01% 891
2022
Q1 		$2.52M Hold
320,291
– – ﹤0.01% 883
2021
Q4 		$2.7M Hold
320,291
– – ﹤0.01% 857
2021
Q3 		$8.97M Hold
320,291
– – 0.02% 720
2021
Q2 		$12.5M Hold
320,291
– – 0.02% 636
2021
Q1 		$15.1M Sell
320,291
-11,229
-3% -$619K 0.03% 552
2020
Q4 		$13M Buy
331,520
+111,520
+51% +$3.8M 0.03% 531
2020
Q3 		$5.61M Hold
220,000
– – 0.01% 617
2020
Q2 		$16M Hold
220,000
– – 0.04% 438
2020
Q1 		$11.6M Buy
220,000
+20,000
+10% +$1.34M 0.03% 436
2019
Q4 		$16.4M Buy
200,000
+80,000
+67% +$5.64M 0.04% 420
2019
Q3 		$6.78M Hold
120,000
– – 0.02% 586
2019
Q2 		$14.3M Buy
120,000
+16,000
+15% +$2.68M 0.04% 440
2019
Q1 		$19.1M Hold
104,000
– – 0.05% 389
2018
Q4 		$18.6M Buy
104,000
+25,000
+32% +$5.45M 0.05% 354
2018
Q3 		$25.3M Sell
79,000
-11,000
-12% -$3.9M 0.06% 353
2018
Q2 		$36M Sell
90,000
-2,558
-3% -$1.12M 0.08% 274
2018
Q1 		$33.2M Buy
92,558
+9,266
+11% +$3.44M 0.08% 297
2017
Q4 		$33M Buy
83,292
+3,296
+4% +$1.36M 0.07% 305
2017
Q3 		$34.1M Buy
79,996
+1,996
+3% +$536K 0.08% 294
2017
Q2 		$12.5M Hold
78,000
– – 0.03% 520
2017
Q1 		$9.75M Hold
78,000
– – 0.02% 541
2016
Q4 		$9.46M Buy
+78,000
New +$12.2M 0.03% 541

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Adage Capital Partners's ABEO Position: Q4 2025 in Review

Adage Capital Partners sold out of Abeona Therapeutics (ABEO) in Q4 2025, closing a stake of 3,047,985 shares — an estimated $16.1M sold.

Adage Capital Partners first reported a position in ABEO in Q4 2016 and held it in 36 quarters. The position peaked at $36M in Q2 2018. 104 funds tracked by Wall St. Rank hold ABEO as of Q4 2025.

  • Adage Capital Partners reported no remaining Abeona Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 3,047,985 Abeona Therapeutics shares in Q4 2025, an estimated $16.1M.
  • Adage Capital Partners first reported a position in Abeona Therapeutics in Q4 2016 and held it in 36 quarters.
  • Adage Capital Partners's Abeona Therapeutics position peaked at $36M in Q2 2018.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.